Cardiovascular disease and COVID-19: les liaisons dangereuses.


Journal

European journal of preventive cardiology
ISSN: 2047-4881
Titre abrégé: Eur J Prev Cardiol
Pays: England
ID NLM: 101564430

Informations de publication

Date de publication:
Jul 2020
Historique:
pubmed: 12 5 2020
medline: 7 7 2020
entrez: 12 5 2020
Statut: ppublish

Résumé

Patients with cardiovascular risk factors or established cardiovascular disease have an increased risk of developing coronavirus disease 19 and have a worse outcome when infected, but translating this notion into effective action is challenging. At present it is unclear whether cardiovascular therapies may reduce the likelihood of infection, or improve the survival of infected patients. Given the crucial importance of this issue for clinical cardiologists and all specialists dealing with coronavirus disease 19, we tried to recapitulate the current evidence and provide some practical recommendations.

Identifiants

pubmed: 32391719
doi: 10.1177/2047487320924501
pmc: PMC7218353
doi:

Substances chimiques

Cardiovascular Agents 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1017-1025

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Références

Crit Care Med. 2011 Nov;39(11):2440-6
pubmed: 21725239
BMJ. 2012 Jul 11;345:e4260
pubmed: 22786934
JAMA Cardiol. 2020 Jul 1;5(7):811-818
pubmed: 32219356
PLoS One. 2009 Nov 30;4(11):e8087
pubmed: 19956645
Nature. 2013 Mar 14;495(7440):251-4
pubmed: 23486063
Antiviral Res. 2013 Sep;99(3):417-35
pubmed: 23831494
JAMA. 2013 Oct 23;310(16):1692-700
pubmed: 24108510
Nat Med. 2005 Aug;11(8):875-9
pubmed: 16007097
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632
N Engl J Med. 2020 Apr 23;382(17):1653-1659
pubmed: 32227760
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Curr Opin Pharmacol. 2018 Jun;40:9-17
pubmed: 29288933
Proc (Bayl Univ Med Cent). 2018 Oct 26;31(4):419-423
pubmed: 30948970
Circ Res. 2020 May 8;126(10):1443-1455
pubmed: 32252591
Chest. 2007 Apr;131(4):1006-12
pubmed: 17426203
JAMA. 2003 Jun 4;289(21):2801-9
pubmed: 12734147
Circulation. 1995 Aug 1;92(3):657-71
pubmed: 7634481
Eur Respir J. 2018 Jun 21;51(6):
pubmed: 29903860
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
BMJ. 2011 Apr 06;342:d1642
pubmed: 21471172
Clin Res Cardiol. 2020 May;109(5):531-538
pubmed: 32161990
Diabetes Res Clin Pract. 2020 Apr;162:108125
pubmed: 32224164
Eur Heart J. 2020 May 14;41(19):1858
pubmed: 32227120
Arch Acad Emerg Med. 2020 Mar 24;8(1):e35
pubmed: 32232218
Circulation. 2020 Jun 9;141(23):1930-1936
pubmed: 32243205
J Infect Dis. 2012 Jan 1;205(1):13-9
pubmed: 22170954
Hellenic J Cardiol. 2020 Jan - Feb;61(1):42-45
pubmed: 32251729
Am J Respir Crit Care Med. 2020 Jun 1;201(11):1380-1388
pubmed: 32275452
J Thromb Haemost. 2020 Apr;18(4):844-847
pubmed: 32073213
Am J Hypertens. 2015 Jan;28(1):15-21
pubmed: 24842388
Intensive Care Med. 2020 Apr;46(4):586-590
pubmed: 32125455
Intensive Care Med. 2020 May;46(5):846-848
pubmed: 32125452
Clin Infect Dis. 2012 Dec;55(11):1466-73
pubmed: 22918991
JCI Insight. 2019 Oct 17;4(20):
pubmed: 31550243
BMJ. 2020 Mar 26;368:m1091
pubmed: 32217556
Int J Infect Dis. 2016 Aug;49:129-33
pubmed: 27352628
J Am Coll Cardiol. 2020 May 12;75(18):2372-2375
pubmed: 32199938
J Thromb Haemost. 2020 Apr;18(4):786-787
pubmed: 32212240
Eur Heart J. 2021 Jan 7;42(2):206
pubmed: 32176300
J Thromb Thrombolysis. 2021 May;51(4):1107-1110
pubmed: 32246317
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Lancet Respir Med. 2020 May;8(5):506-517
pubmed: 32272080
Epidemiol Infect. 2010 Sep;138(9):1281-8
pubmed: 20109259
Thorax. 2003 Aug;58(8):686-9
pubmed: 12885985
Int J Infect Dis. 2020 May;94:91-95
pubmed: 32173574
Sci China Life Sci. 2020 Mar;63(3):364-374
pubmed: 32048163
J Infect. 2020 Jun;80(6):639-645
pubmed: 32240670
Eur Respir J. 2020 May 14;55(5):
pubmed: 32217650
J Thromb Haemost. 2020 May;18(5):1094-1099
pubmed: 32220112
Drug Dev Res. 2020 Aug;81(5):537-540
pubmed: 32129518
Clin Sci (Lond). 2007 Jun;112(7):375-84
pubmed: 17324119
N Engl J Med. 2020 Apr 23;382(17):e38
pubmed: 32268022

Auteurs

Andrea Barison (A)

Cardiology Division, Fondazione Toscana Gabriele Monasterio, Italy.
Insitute of Life Sciences, Scuola Superiore Sant'Anna, Italy.

Alberto Aimo (A)

Insitute of Life Sciences, Scuola Superiore Sant'Anna, Italy.
University Hospital of Pisa, Italy.

Vincenzo Castiglione (V)

Insitute of Life Sciences, Scuola Superiore Sant'Anna, Italy.
University Hospital of Pisa, Italy.

Chiara Arzilli (C)

University Hospital of Pisa, Italy.

Josep Lupón (J)

Heart Institute, Hospital Universitari Germans Trias i Pujol, Spain.
CIBERCV, Instituto de Salud Carlos III, Spain.

Pau Codina (P)

Heart Institute, Hospital Universitari Germans Trias i Pujol, Spain.
CIBERCV, Instituto de Salud Carlos III, Spain.

Evelyn Santiago-Vacas (E)

Heart Institute, Hospital Universitari Germans Trias i Pujol, Spain.
CIBERCV, Instituto de Salud Carlos III, Spain.

Germán Cediel (G)

Heart Institute, Hospital Universitari Germans Trias i Pujol, Spain.
CIBERCV, Instituto de Salud Carlos III, Spain.

Michele Emdin (M)

Cardiology Division, Fondazione Toscana Gabriele Monasterio, Italy.
Insitute of Life Sciences, Scuola Superiore Sant'Anna, Italy.

Antoni Bayes-Genis (A)

Heart Institute, Hospital Universitari Germans Trias i Pujol, Spain.
CIBERCV, Instituto de Salud Carlos III, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH